Slide 1: Invitation to Subscribe for Shares
ADVERTISEMENT INVITATION TO SUBSCRIBE FOR SHARES SUBSCRIPTION PERIOD 2 May – 16 May 2025 IMPORTANT INFORMATION This information folder constitutes marketing and is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council. The invitation to subscr
Slide 2: Curasight: Business Model and Path Forward
Rights Issue 2025 – Curasight A/S CURASIGHT Curasight A/S (“Curasight”or the “Company”) is the pioneer behind the novel imaging and therapeutic approach based on the urokinase-type plasminogen activator receptor (uPAR). The technology minimizes Byt ut bild irradiation of healthy tissue by combining
Slide 3: Motive for the Offer and The Offer in Brief
Rights Issue 2025 – Curasight A/S MOTIVE FOR THE OFFER The Rights Issue will, if fully subscribed, provide the Company with approximately DKK 100 million in gross proceeds before deduction of transaction costs. The costs related to the Rights Issue are estimated at full subscription, to amount to a
Slide 4: CEO Ulrich Krasilnikoff Comments and Investment Highlights
Rights Issue 2025 – Curasight A/S CEO ULRICH KRASILNIKOFF COMMENTS Looking back on 2024, I am proud of the progress The therapeutic strategy with uTREAT® we made in our clinical development activities In November 2024, we announced aggressive brain against a backdrop of a very challenging cancer (Hi
Slide 5: Terms and Conditions
Rights Issue 2025 – Curasight A/S TERMS AND CONDITIONS Preferential Rights Subscription for Remaining Shares Allocation of New Shares Subscribed for Without Subscription Rights Each holder of existing shares registered with Euronext Securities as of the record date, The general public and existing s
Slide 6: Curasight A/S contact details
ADVERTISEMENT Curasight A/S Ole Maaløes Vej 3 DK-2200 København N